PIK3CA mutation in HPV-associated OPSCC patients receiving deintensified chemoradiation

Brian T. Beaty, Dominic H. Moon, Colette J. Shen, Robert J. Amdur, Jared Weiss, Juneko Grilley-Olson, Shetal Patel, Adam Zanation, Trevor G. Hackman, Brian Thorp, Jeffrey M. Blumberg, Samip N. Patel, Mark C. Weissler, Wendell G. Yarbrough, Nathan C. Sheets, Joel S. Parker, D. Neil Hayes, Karen E. Weck, Lori A. Ramkissoon, William M. MendenhallRoi Dagan, Xianming Tan, Gaorav P. Gupta, Bhishamjit S. Chera

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


PIK3CA is the most frequently mutated gene in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). Prognostic implications of such mutations remain unknown. We sought to elucidate the clinical significance of PIK3CA mutations in HPV-associated OPSCC patients treated with definitive chemoradiation (CRT). Seventyseven patients with HPV-associated OPSCC were enrolled on two phase II clinical trials of deintensified CRT (60 Gy intensitymodulated radiotherapy with concurrent weekly cisplatin). Targeted next-generation sequencing was performed. Of the 77 patients, nine had disease recurrence (two regional, four distant, three regional and distant). Thirty-four patients had mutation( s) identified; 16 had PIK3CA mutations. Patients with wild-type-PIK3CA had statistically significantly higher 3-year disease-free survival than PIK3CA-mutant patients (93.4%, 95% confidence interval [CI] = 85.0% to 99.9% vs 68.8%, 95% CI = 26.7% to 89.8%; P=.004). On multivariate analysis, PIK3CA mutation was the only variable statistically significantly associated with disease recurrence (hazard ratio = 5.71, 95% CI = 1.53 to 21.3; P=.01). PIK3CA mutation is associated with worse diseasefree survival in a prospective cohort of newly diagnosed HPV-associated OPSCC patients treated with deintensified CRT.

Original languageEnglish (US)
Pages (from-to)855-858
Number of pages4
JournalJournal of the National Cancer Institute
Issue number8
StatePublished - Aug 1 2020
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'PIK3CA mutation in HPV-associated OPSCC patients receiving deintensified chemoradiation'. Together they form a unique fingerprint.

Cite this